Compare IBEX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | VALN |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.0M | 582.2M |
| IPO Year | 2017 | 2021 |
| Metric | IBEX | VALN |
|---|---|---|
| Price | $45.73 | $5.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $42.00 | $12.25 |
| AVG Volume (30 Days) | ★ 94.8K | 18.7K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.63 | N/A |
| EPS | ★ 3.13 | N/A |
| Revenue | ★ $644,076,000.00 | N/A |
| Revenue This Year | $10.59 | N/A |
| Revenue Next Year | $6.75 | $87.65 |
| P/E Ratio | $14.67 | ★ N/A |
| Revenue Growth | ★ 15.37 | N/A |
| 52 Week Low | $25.94 | $4.75 |
| 52 Week High | $46.21 | $12.18 |
| Indicator | IBEX | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 66.27 | 41.41 |
| Support Level | $29.07 | $5.51 |
| Resistance Level | N/A | $6.60 |
| Average True Range (ATR) | 1.17 | 0.21 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 55.87 | 16.21 |
IBEX Ltd delivers business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. The company's services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital), and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare, among others, and derives maximum revenue from the United States.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.